Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial

Javier Cortés; Hope S. Rugo; Ahmad Awada; Chris Twelves; Edith A. Perez; Seock‐Ah Im; Patricia Gómez-Pardo; Lee S. Schwartzberg; Véronique Dièras; Denise A. Yardley; David A. Potter; Audrey Mailliez; Alvaro Moreno‐Aspitia; Jin-Seok Ahn; Carol Zhao; Ute Hoch; Mary Tagliaferri; Alison L. Hannah; Joyce O’Shaughnessy

doi:10.1007/s10549-017-4304-7

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

The significant improvement in survival in BCBM patients provides encouraging data for EP in this difficult-to-treat subgroup of patients. A phase three trial of EP in BCBM patients is underway (ClinicalTrials.gov NCT02915744).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cortés et al. (2017) studied this question.

synapsesocial.com/papers/69d8d88a13e0539d74bedc78 https://doi.org/10.1007/s10549-017-4304-7

View Full Paper

Ask AI

Bookmark

Share

Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial

Ask about this paper

Abstract

Discussion

Cite This Study

Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading